These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1453702)

  • 21. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
    Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
    Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
    Sarris J; LaPorte E; Schweitzer I
    Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and synthesis of TNF-alpha release inhibitors from Fijian kawa (Piper methysticum).
    Hashimoto T; Suganuma M; Fujiki H; Yamada M; Kohno T; Asakawa Y
    Phytomedicine; 2003 May; 10(4):309-17. PubMed ID: 12809361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava).
    Unger M; Holzgrabe U; Jacobsen W; Cummins C; Benet LZ
    Planta Med; 2002 Dec; 68(12):1055-8. PubMed ID: 12494328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some visual effects caused by the beverage kava.
    Garner LF; Klinger JD
    J Ethnopharmacol; 1985 Jul; 13(3):307-11. PubMed ID: 4058033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive effects of kava (Piper methysticum): a systematic review.
    LaPorte E; Sarris J; Stough C; Scholey A
    Hum Psychopharmacol; 2011 Mar; 26(2):102-11. PubMed ID: 21437989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro.
    Weiss J; Sauer A; Frank A; Unger M
    Drug Metab Dispos; 2005 Nov; 33(11):1580-3. PubMed ID: 16051732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of plant extracts by NIRS: simultaneous determination of kavapyrones and water in dry extracts of Piper methysticum Forst.
    Gaub M; Roeseler Ch; Roos G; Kovar KA
    J Pharm Biomed Anal; 2004 Nov; 36(4):859-64. PubMed ID: 15533680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality aspects of traditional and industrial Kava-extracts.
    Loew D; Franz G
    Phytomedicine; 2003; 10(6-7):610-2. PubMed ID: 13678252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A chemical and pharmacological investigation of Piper methysticum Forst.
    KLOHS MW; KELLER F; WILLIAMS RE; TOEKES MI; CRONHEIM GE
    J Med Pharm Chem; 1959 Feb; 1(1):95-103. PubMed ID: 13655031
    [No Abstract]   [Full Text] [Related]  

  • 31. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster).
    Martin AC; Johnston E; Xing C; Hegeman AD
    PLoS One; 2014; 9(11):e111572. PubMed ID: 25365244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biopharmaceutical evaluation of kavain in Piper methysticum G. Forst dried extract: Equilibrium solubility and intestinal permeability in Caco-2 cell model.
    Santos RRDS; Ramos MC; Ferreira JV; Gonçalves JE; César IC
    J Ethnopharmacol; 2022 Oct; 296():115480. PubMed ID: 35716919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A less than Pacific odyssey: the use of kava.
    Mack RB
    N C Med J; 1999; 60(2):91-3. PubMed ID: 10344133
    [No Abstract]   [Full Text] [Related]  

  • 34. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC).
    Lebot V; Do TK; Legendre L
    Food Chem; 2014 May; 151():554-60. PubMed ID: 24423570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kavalactones fail to inhibit alcohol dehydrogenase in vitro.
    Anke J; Fu S; Ramzan I
    Phytomedicine; 2006 Feb; 13(3):192-5. PubMed ID: 16428028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kava: Piper methysticum.
    Pepping J
    Am J Health Syst Pharm; 1999 May; 56(10):957-8, 960. PubMed ID: 10365719
    [No Abstract]   [Full Text] [Related]  

  • 37. A systematic review of the safety of kava extract in the treatment of anxiety.
    Stevinson C; Huntley A; Ernst E
    Drug Saf; 2002; 25(4):251-61. PubMed ID: 11994028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence.
    Teschke R; Qiu SX; Xuan TD; Lebot V
    Phytother Res; 2011 Sep; 25(9):1263-74. PubMed ID: 21442674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kava hepatotoxicity--a clinical review.
    Teschke R
    Ann Hepatol; 2010; 9(3):251-65. PubMed ID: 20720265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.
    Savage KM; Stough CK; Byrne GJ; Scholey A; Bousman C; Murphy J; Macdonald P; Suo C; Hughes M; Thomas S; Teschke R; Xing C; Sarris J
    Trials; 2015 Nov; 16():493. PubMed ID: 26527536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.